Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Angiodynamics, Inc. (ANGO)
:ANGO
Holding ANGO?
Track your performance easily
ANGO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.26 - $13.13
Previous CloseN/A
Volume2.49M
Average Volume (3M)843.18K
Market Cap
$516.75M
Enterprise Value$234.41M
Total Cash (Recent Filing)$48.76M
Total Debt (Recent Filing)$91.32M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Apr 03, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.58
Shares Outstanding40,465,710
10 Day Avg. Volume1,299,590
30 Day Avg. Volume843,178
Standard Deviation0.14
R-Squared0.05
Alpha-0.00603
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.68
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit1.52
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$15.33Price Target Upside20.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
AngioDynamics News
Bulls Say, Bears Say
Bulls Say
Clinical Data And Market ExpansionThe company's pivotal PRESERVE clinical study showed 84% of men were free from in-field, clinically significant disease at 12 months post-procedure, highlighting the effectiveness of the NanoKnife system.
Market Growth And Financial GuidanceManagement reiterated entire FY25 guidance, with revenue expected in the range of $282M-$288M, highlighting strong growth expectations driven by the Med Tech segment.
Regulatory ApprovalFDA approves NanoKnife System for prostate tissue ablation, providing a minimally invasive option for prostate treatment compared to conventional surgery or radiotherapy.
Bears Say
Cash FlowThe stock reaction is driven by the seasonally high cash burn.
Future ProspectsNanoKnife has the most catalysts ahead, but the impact of those may not come until late FY25 or early FY26.
RevenueThe stock reaction is driven by missing the consensus revenue estimate.
---
Ownership Overview
4.17% Insiders
17.57% Mutual Funds
1.87% Other Institutional Investors
64.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANGO FAQ
What was Angiodynamics, Inc.’s price range in the past 12 months?
Angiodynamics, Inc. lowest stock price was $5.26 and its highest was $13.13 in the past 12 months.
What is Angiodynamics, Inc.’s market cap?
Angiodynamics, Inc.’s market cap is $516.75M.
When is Angiodynamics, Inc.’s upcoming earnings report date?
Angiodynamics, Inc.’s upcoming earnings report date is Apr 03, 2025 which is in 75 days.
How were Angiodynamics, Inc.’s earnings last quarter?
Angiodynamics, Inc. released its earnings results on Jan 08, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.07.
Is Angiodynamics, Inc. overvalued?
According to Wall Street analysts Angiodynamics, Inc.’s price is currently Undervalued.
Does Angiodynamics, Inc. pay dividends?
Angiodynamics, Inc. does not currently pay dividends.
What is Angiodynamics, Inc.’s EPS estimate?
Angiodynamics, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Angiodynamics, Inc. have?
Angiodynamics, Inc. has 40,465,710 shares outstanding.
What happened to Angiodynamics, Inc.’s price movement after its last earnings report?
Angiodynamics, Inc. reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went up 37.66%.
Which hedge fund is a major shareholder of Angiodynamics, Inc.?
Among the largest hedge funds holding Angiodynamics, Inc.’s share is Royce & Associates LLC. It holds Angiodynamics, Inc.’s shares valued at 8M.
---
AngioDynamics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (20.05% Upside)
$15.33 (20.05% Upside)
Blogger Sentiment
Bullish
ANGO Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 374.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.98%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
-41.65%
Trailing 12-Months
Company Description
Angiodynamics, Inc.
AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.
---
ANGO Company Deck
---
ANGO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in revenue growth and profitability, especially within the Med Tech segment, driven by innovations like AlphaVac and NanoKnife. However, challenges persist in Med Device revenue stagnation and manufacturing transition costs, tempering overall financial improvements.Read More>---
ANGO Stock 12 Month Forecast
Average Price Target
$15.33
▲(20.05% Upside)
Technical Analysis
Best Analysts Covering ANGO
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+53.64%
reiterated a buy rating 8 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +53.64% per trade.
---